Skip to main content Skip to main navigation Skip to search Skip to footer

HCL Technologies

In Vitro Diagnostic Regulation(IVDR) Overview

In Vitro Diagnostic Regulation(IVDR) Overview

The new and stringent requirements related to clinical evidence has already created chaos among the industry. It necessitates the manufacturer to go through the existing evidence and ensure that it is in compliance with the new definitions and performance evaluation requirements set by IVDR.

Importantly, for classification rules and companion diagnostics guidance documents like MED DEVs from the Commission would really benefit the industry. Having all these challenges, effective from 27 May 2022, manufacturers without compliance to IVDR, may not be able to market their product in the European Union. At HCL Technologies, a wide pool of regulatory consultants are involved in providing their expert services to the industry to cater to the change within the required timeframe.

DOWNLOAD THE WHITEPAPER

Contact Us
MAX CHARACTERS: 10,000

We will treat any information you submit with us as confidential.

HCL provides software and services to U.S. Federal Government customers through its partner ImmixGroup, Inc. Please contact ImmixGroup, Inc. at HCLFederal@immixgroup.com

We will treat any information you submit with us as confidential.